Cardiac biomarkers are also called cardiac markers. In a condition when the heart is damaged or stressed, cardiac biomarkers (endogenous substances including enzymes, hormones, and proteins) are released into the blood. Generally, they are used to diagnose heart attack and acute coronary syndrome (ACS) or conditions associated with insufficient blood flow to the heart. Among cardiac biomarker tests, troponin is the biomarker test of choice for detecting heart damage. The test is performed with a blood sample using a needle to draw blood from a vein in the hand or arm. Troponin is elevated within a few hours of heart damage and stays elevated up to two weeks. The test performed for several hours helps diagnose a heart attack. Cardiac markers are also used in the diagnosis and risk stratification of patients with chest pain. There are other established biomarkers, such as myoglobin (test used along with troponin for early detection of heart attack) and creatinine kinase isoenzymes (also called cardiac enzyme, is linked with injury of heart muscle and detection of a second heart attack anticipated shortly after the first).
There are a number of factors that impact the growth of the cardiac biomarkers market. Some of the key factors include rise in demand for diagnostic and testing of various cardiovascular diseases, development and advancement in cardiac biomarkers, and growth in patient population suffering from cardiovascular diseases. Other key growth drivers include rise in the number of new cardiovascular cases diagnosed each year and increase in demand for disease-specific treatment in which cardiac biomarkers are used. Increasing prevalence of cardiovascular diseases is expected to boost the cardiac biomarkers market during the forecast period. According to World Health Organization, about 17.7 million people die each year from cardiovascular diseases (CVDs) and it is estimated to be the cause of 31% of the total deaths worldwide. Around 80% of all CVD deaths is due to heart attacks and strokes. However, the cardiac biomarkers market is witnessing restraints due to the development of other methods for diagnosis of cardiovascular diseases, along with high cost of procedure, lack of full proof assurance, and steep competition among existing players.
The global cardiac biomarkers market can be classified based on type, application, and geography. Based on type, the cardiac biomarkers market can be segmented into creatine kinase (CK-MB), troponins T and I, myoglobin, B-type natriuretic peptide (BNPs), N-terminal pro b-type natriuretic peptide (NT-proBNP), ischemia-modified albumin (IMA), and others. Troponins I and T are the leading revenue-generating segment in the global cardiac biomarkers market due to its prodigious specificity and ability to accurately detect the cardiac events of Acute Coronary Syndrome (ACS). In terms of application, the cardiac biomarkers market can be divided into congestive heart failure, myocardial infarction, acute coronary syndrome, atherosclerosis, and others.
Geographically, the cardiac biomarkers market can be classified into five regional markets, such as, North America (U.S. and Canada), Europe (Germany, France, U.K., etc.), Asia Pacific (Australia & New Zealand, China, Japan, India, etc.), Latin America, and Middle East & Africa. North America and Europe dominate the global cardiac biomarkers market due to increasing patient population suffering from cardiovascular diseases (angina pectoris, myocardial infraction, and others), lack of physical activity, and unhealthy diet. In addition, India, Southeast Asia, and China are the emerging markets for cardiac biomarkers due to rising incidence of coronary artery diseases in these regions. Initiatives taken by the government in Asia Pacific toward development of health care infrastructure are also expected to boost the growth of the cardiac biomarkers market in the region.
Key companies operating in the global cardiac biomarkers market are Abbott Laboratories, Beckman Coulter, Inc. bioMérieux SA, Johnson and Johnson, Olympus Corporation, Siemens Healthcare GmbH, F. Hoffmann-La Roche Ltd., PerkinElmer Inc., Tosoh Corporation, etc.
The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.
The study is a source of reliable data on:
- Market segments and sub-segments
- Market trends and dynamics
- Supply and demand
- Market size
- Current trends/opportunities/challenges
- Competitive landscape
- Technological breakthroughs
- Value chain and stakeholder analysis
The regional analysis covers:
- North America (U.S. and Canada)
- Latin America (Mexico, Brazil, Peru, Chile, and others)
- Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, and Luxembourg)
- Eastern Europe (Poland and Russia)
- Asia Pacific (China, India, Japan, ASEAN, Australia, and New Zealand)
- Middle East and Africa (GCC, Southern Africa, and North Africa)
The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industry’s value chain.
A separate analysis of prevailing trends in the parent market, macro- and micro-economic indicators, and regulations and mandates is included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period.
Highlights of the report:
- A complete backdrop analysis, which includes an assessment of the parent market
- Important changes in market dynamics
- Market segmentation up to the second or third level
- Historical, current, and projected size of the market from the standpoint of both value and volume
- Reporting and evaluation of recent industry developments
- Market shares and strategies of key players
- Emerging niche segments and regional markets
- An objective assessment of the trajectory of the market
- Recommendations to companies for strengthening their foothold in the market
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.